journal
MENU ▼
Read by QxMD icon Read
search

Innovations in Clinical Neuroscience

journal
https://www.readbyqxmd.com/read/27975002/delirium-or-dementia
#1
Steven Lippmann, Malathi Latha Perugula
No abstract text is available yet for this article.
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27975001/consent-to-treatment-of-minors-revisited
#2
Ann McNary
No abstract text is available yet for this article.
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27975000/cariprazine-for-schizophrenia-and-bipolar-disorder
#3
REVIEW
Jonathan R Scarff
Schizophrenia and bipolar disorder are associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms of schizophrenia as well as manic or mixed episodes of bipolar disorder, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. Cariprazine was recently approved to treat adult patients with schizophrenia and manic or mixed episodes. It was well-tolerated and adverse reactions included akathisia, extrapyramidal symptoms, nausea, or constipation...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974999/eszopiclone-induced-parasomnia-with-suicide-attempt-a-case-report
#4
J Gibson Pennington, Jeffrey Guina
Eszopiclone is a benzodiazepine-like hypnotic that is commonly prescribed to treat insomnia. However, eszopiclone's efficacy has been questionable in several clinical trials, and its pharmacologic profile makes its effects on sleep and behavior difficult to predict. We report a case demonstrating an instance of eszopiclone-induced parasomnia involving paranoia and a suicide attempt in a patient taking eszopiclone. We explore possible biochemical explanations examining the pharmacologic profile of eszopiclone and its potential for drug-drug interactions, especially with concomitant administration of monoaminergic medications such as antidepressants...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974998/assessment-of-cognitive-and-neurologic-recovery-in-ischemic-stroke-drug-trials-results-from-a-randomized-double-blind-placebo-controlled-study
#5
Franco Di Cesare, Jessica Mancuso, Brian Silver, Peter T Loudon
Objective. Ischemic stroke is a serious medical condition with limited therapeutic options. The evaluation of the therapeutic potential of novel pharmacological interventions is carried-out in Phase II trials. The study design, primarily intended to evaluate efficacy and safety, is a balance between utilizing as few patients as possible to minimize safety risk and enrolling sufficient patients to detect unambiguous efficacy signals. We sought to determine whether post-stroke recovery outcomes based on behavioral measures of cognitive and motor impairment yielded additional information beyond that of clinician-based methods...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974997/the-depression-inventory-development-workgroup-a-collaborative-empirically-driven-initiative-to-develop-a-new-assessment-tool-for-major-depressive-disorder
#6
REVIEW
Anthony L Vaccarino, Kenneth R Evans, Amir H Kalali, Sidney H Kennedy, Nina Engelhardt, Benicio N Frey, John H Greist, Kenneth A Kobak, Raymond W Lam, Glenda MacQueen, Roumen Milev, Franca M Placenza, Arun V Ravindran, David V Sheehan, Terrence Sills, Janet B W Williams
The Depression Inventory Development project is an initiative of the International Society for CNS Drug Development whose goal is to develop a comprehensive and psychometrically sound measurement tool to be utilized as a primary endpoint in clinical trials for major depressive disorder. Using an iterative process between field testing and psychometric analysis and drawing upon expertise of international researchers in depression, the Depression Inventory Development team has established an empirically driven and collaborative protocol for the creation of items to assess symptoms in major depressive disorder...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27974996/performance-reliability-usability-and-safety-of-the-id-cap-system-for-ingestion-event-monitoring-in-healthy-volunteers-a-pilot-study
#7
Glen P Flores, Brian Peace, Tony C Carnes, Susan L Baumgartner, D Eric Buffkin, Neil R Euliano, Larry N Smith
Background: Nonadherence to prescribed medications is an important consideration in the clinical management of patients and in clinical research and drug development. The ID-Cap System is a novel technology that provides an objective measure of medication ingestion and enables real-time reporting of verified medication adherence data at the dose level. The ID-Cap System consists of an ingestible microsensor that is embedded in an oral dosage form and, once activated by stomach fluid, communicates digital messages to an external wearable reader to confirm ingestion...
September 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672489/fahr-s-disease-or-fahr-s-syndrome
#8
Malathi Latha Perugula, Steven Lippmann
No abstract text is available yet for this article.
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672488/professional-liability-for-forensic-activities-liability-without-a-treatment-relationship
#9
Donna Vanderpool
No abstract text is available yet for this article.
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672487/a-case-of-treatment-resistant-depression-and-body-dysmorphic-disorder-the-role-of-electroconvulsive-therapy-revisited
#10
Ram S Mahato, Maria Chona P San Gabriel, Carrol T Longshore, David B Schnur
Body dysmorphic disorder is a common, often disabling condition, and is frequently comorbid with major depressive disorder. Selective serotonin reuptake inhibitors constitute first line set of somatic interventions but the management of refractory patients remains challenging. Electroconvulsive therapy, an often highly beneficial treatment for medication resistant-depression, is not considered an effective therapeutic alternative for treatment refractory body dysmorphic disorder. Here we present a 50-year-old woman with body dysmorphic disorder and comorbid major depressive disorder who remained incapacitated and suicidal despite several trials with selective serotonin reuptake inhibitors and antipsychotic medication...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672486/the-potential-role-of-t-helper-cell-22-and-il-22-in-immunopathogenesis-of-multiple-sclerosis
#11
REVIEW
Nazanin Arjomand Fard, Gholamreza Azizi, Abbas Mirshafiey
Multiple sclerosis is a complex disease with many different immune cells involved in its pathogenesis. Newly identified T helper cell 22 (Th22) is a subset of CD4(+) T cells with specific properties apart from other known CD4(+) T cell subsets with distinguished function and gene expression. Th22 cells are characterized by production of a distinct profile of effector cytokines, including interleukin (IL)-22, IL-13, and tumor necrosis factor-α (TNF- α). The frequency of Th22 and related cytokine IL-22 are increased in various autoimmune diseases...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672485/brexpiprazole-a-new-treatment-option-for-schizophrenia
#12
REVIEW
Jonathan R Scarff
Schizophrenia occurs in approximately 0.3 to 0.7 percent of the world's population and is associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. This article reviews brexpiprazole, a medication recently approved to treat patients with schizophrenia. Brexpiprazole was well-tolerated, and adverse reactions were statistically insignificant...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672484/pharmaceutical-innovation-in-the-treatment-of-schizophrenia-and-mental-disorders-compared-with-other-diseases
#13
Joanna P MacEwan, Seth Seabury, Myrlene Sanon Aigbogun, Siddhesh Kamat, Emma van Eijndhoven, Clement Francois, Crystal Henderson, Leslie Citrome
OBJECTIVES: The objectives of this study were to assess the level of private and public investment in research and development of treatments for schizophrenia and other mental disorders compared to other diseases in order to present data on the economic burden and pharmaceutical innovation by disease area, and to compare the level of investment relative to burden across different diseases. DESIGN: The levels of investment and pharmaceutical innovation relative to burden across different diseases were assessed...
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672483/criminal-behavior-and-borderline-personality-correlations-among-four-measures
#14
Randy A Sansone, Martin Sellbom, Douglas A Songer
No abstract text is available yet for this article.
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27672482/gabapentin-abuse-in-a-patient-with-comorbid-mood-and-substance-use-disorders
#15
Oleg V Tcheremissine, Durga Prasad Bestha
No abstract text is available yet for this article.
July 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27803841/physician-prescribing-practices-of-vitamin-d-in-a-psychiatric-hospital
#16
Kimberly B Mulcahy, Eileen Trigoboff, Lewis Opler, Tammie Lee Demler
Vitamin D supplementation has become an increasingly popular prescribing practice, despite our limited knowledge of both the definition and degree of deficiency as well as the expected benefits or risks of exogenous administration. Many of the hypothesized benefits of vitamin D supplementation include a variety of improvements in mental health; however, these claims are not consistently or robustly supported by current research. In this paper, we provide a brief overview of what is currently known about vitamin D deficiency and about outcomes of supplementation as well as a summary of the data relative to prescribing practices for inpatients in an urban psychiatric hospital...
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27800286/exit-strategy-planning-for-the-unexpected-closure-of-your-practice
#17
REVIEW
Ann McNary
No abstract text is available yet for this article.
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27800285/remission-of-psychosis-in-treatment-resistant-schizophrenia-following-a-seizure-a-case-report
#18
Hena Jawaid, Sana Younus, Hanif Mesiya
The authors report a case of treatment-resistant schizophrenia in a 22-year-old woman, who, despite multiple trials of antipsychotics, did not respond to treatment. Clozapine treatment was initiated, but the patient's symptoms did not remit until after she had a clozapine-induced seizure. The authors discuss the importance in considering that electroconvulsive therapy may be effective in reducing positive and negative symptoms in patients suffering from treatment-resistant schizophrenia.
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27800284/the-standard-for-clinicians-interview-in-psychiatry-scip-a-clinician-administered-tool-with-categorical-dimensional-and-numeric-output-conceptual-development-design-and-description-of-the-scip
#19
REVIEW
Ahmed Aboraya, Henry Nasrallah, Srinivas Muvvala, Ahmed El-Missiry, Hader Mansour, Cheryl Hill, Daniel Elswick, Elizabeth C Price
Existing standardized diagnostic interviews (SDIs) were designed for researchers and produce mainly categorical diagnoses. There is an urgent need for a clinician-administered tool that produces dimensional measures, in addition to categorical diagnoses. The Standard for Clinicians' Interview in Psychiatry (SCIP) is a method of assessment of psychopathology for adults. It is designed to be administered by clinicians and includes the SCIP manual and the SCIP interview. Clinicians use the SCIP questions and rate the responses according to the SCIP manual rules...
May 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/27800283/prolactin-levels-after-switching-to-paliperidone-palmitate-in-patients-with-schizophrenia
#20
Masaru Nakamura, Takahiko Nagamine, Goro Sato, Kazue Besho
Objective: The aim of this study was to investigate the tolerability and efficacy of paliperidone palmitate and its effect on the levels of prolactin in patients with schizophrenia. Method: A prospective study was carried out in 22 Japanese middle-aged patients with schizophrenia who were switched from paliperidone-extended release or risperidone long-acting injectable to paliperidone palmitate for a minimum of 12 months. Psychotic symptoms using the 18-item Brief Psychiatric Rating Scale, extrapyramidal symptoms using 9-item Drug-induced Extrapyramidal Symptoms Scale, and plasma prolactin levels using fasting blood samples were assessed at Baseline, and one, three, six, and 12 months...
May 2016: Innovations in Clinical Neuroscience
journal
journal
43359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"